Preview

Medical Genetics

Advanced search

Study of polymorphism of genes of the renin-angiotensin-aldosterone system in patients with non-valvular atrial fibrillation with or without arterial hypertension (pilot study)

https://doi.org/10.25557/2073-7998.2024.04.54-62

Abstract

Atrial fibrillation (AF) is the most common cardiac arrhythmia. AF can occur both in isolation and in a number of diseases. Often, AF and arterial hypertension (AH) coexist, since these nosologies have common risk factors and conditions that increase the incidence of both. According to large clinical studies, the leading role of hypertension in the development of AF has been established. The range of candidate genes involved in the implementation of hypertension is quite wide and includes groups of genes that control various metabolic and homeostatic systems, the disturbances of which are involved in the pathogenesis of cardiovascular diseases. In particular, these are the genes of the renin-angiotensin system. It is relevant to study the genes of the renin-angiotensin-aldosterone system (RAAS) in AF, since the associative effect of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA II) in the prevention of AF has been proven. RAAS blockers can not only reduce the risk of developing new-onset AF in patients, both with and without arterial hypertension, but also prevent relapse of AF. In this study, 68 patients with non-valvular AF were examined. All patients were divided into two groups: patients with atrial fibrillation with hypertension and patients with atrial fibrillation without hypertension. Genetic research methods included DNA isolation and determination of genetic polymorphisms of the RAAS using the polymerase chain reaction method in real time using a thermal cycler and reagents from the DNA-Technology company (Russia). A comparative analysis of polymorphic variants of the RAAS genes: rs4961 ADD1, rs699 AGT, rs4762 AGT, rs5186 AGTR1, rs1403543 AGTR2, rs1799998 CYP11B2, rs5443 GNB3 in patients with AF in the study groups did not reveal statistically significant differences.

About the Authors

O. N. Ogurkova
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



Yu. G. Lugacheva
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



T. E. Suslova
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



I. V. Кulagina
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



M. A. Dragunova
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



E. S. Sitkova
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



O. V. Musatova
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



R. E. Batalov
Cardiology Research Institute; Tomsk National Research Medical Centre of the Russian Academy of Sciences
Russian Federation

111a, Kievskaya st., Tomsk, 634012



References

1. Kirgizova M.A., Batalov R.E., Tatarsky B.A., Popov S.V. Fibrillyaciya predserdij i arterial’naya gipertenziya: sovremennoe predstavlenie o patogeneze, diagnostike i lechenii [Atrial fibrillation and arterial hypertension: modern understanding of pathogenesis, diagnosis and treatment]. Sibirskij zhurnal klinicheskoj i eksperimental’noj mediciny [Siberian Journal of Clinical and Experimental Medicine]. 2019;34(3):13-20. (In Russ.)

2. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021; 42(5): 373-498.

3. Baranova E.I. Fibrillyaciya predserdij u bol’nyh arterial’noj gipertenziej [Atrial fibrillation in patients with arterial hypertension]. Arterial’naya gipertenziya [Arterial hypertension]. 2011; 4: 5-16. (In Russ.)

4. Ponasenko A.V., Sinitsky M.U., Khutornaya M.V. Molekulyarno-geneticheskie markery fibrillyacii predserdij [Molecular genetic markers of atrial fibrillation]. Byulleten’ sibirskoj mediciny [Bulletin of Siberian Medicine]. 2020;19(1):180-189. (In Russ.)

5. Koziolova N.A., Chernyavina A.I. Vzaimosvyaz’ polimorfizma genov s riskom razvitiya hronicheskoj serdechnoj nedostatochnosti u bol’nyh gipertonicheskoj bolezn’yu pri vysokoj priverzhennosti k lecheniyu [The relationship of gene polymorphism with the heart failure risk in patients with hypertension and high adherence to treatment]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2020;25(3):3708. (In Russ.)

6. Tlegenova Zh.Sh., Zholdin B.K., Kudaiberdieva G.Z., Abdrakhmanov A.S. Faktory riska razvitiya fibrillyacii predserdij u bol’nyh arterial’noj gipertenziej s sohranennoj sistolicheskoj funkciej levogo zheludochka [Factors associated with atrial fibrillation in patients with hypertension and preserved left ventricle systolic function]. Kardiologiya [Kardiologiia]. 2019;59(5S):37-46. (In Russ.)

7. Sizova O.V., Paramonova E.K., Wolf Y. et al. Geneticheskiye aspekty preeklampsii i khronicheskoy arterial′noy gipertenzii (Obzor literatury) [Genetic aspects of preeclampsia and chronic arterial hypertension (Literature review)]. Verkhnevolzhskiy meditsinskiy zhurnal [Verkhnevolzhsky medical journal]. 2018;17(3):33-37. (In Russ.)

8. Zelenskaya E.M., Kokh N.V., Kireeva V.V. et al. Assotsiatsiya gena CYP11B2 s riskom razvitiya gipertonicheskoy bolezni i aterotromboticheskikh oslozhneniy [Association of the CYP11B2 gene with the risk of developing hypertension and atherothrombotic complications]. Serdechno-sosudistaya terapiya i profilaktika [Cardiovascular therapy and prevention]. 2016;15(3):63-68. (In Russ.)

9. Elkina A.Y., Akimova N.S., Schwartz Y.G. Polimorfnye varianty genov angiotenzinprevrashchayushchego fermenta, angiotenzinogena, gena receptora 1 tipa k angiotenzinu-ІІ kak geneticheskie prediktory razvitiya arterial’noj gipertonii [Polymorphic variants of the angiotensin-converting enzyme, angiotensinogen, and angiotensin-II receptor type 1 genes as genetic predictors of the development of arterial hypertension]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2021;26(1S):4143. (In Russ.)

10. Khidirova L.D., Osmieva Z.M. Rol′ polimorfizma gena AGTR1 v progressirovanii i razvitii oslozhneniy fibrillyatsii predserdiy v sochetanii s gipertonicheskoy bolezn′yu [The role of AGTR1 gene polymorphism in the progression and development of complications of atrial fibrillation in combination with hypertension]. Meditsinskiy alfavit [Medical alphabet]. 2022;(30):12-18. (In Russ.) .

11. Topal N.P., Ozben B., Hancer V.S. et al. Polymorphisms of the angiotensinconverting enzyme and angiotensinogen gene in patients with atrial fibrillation. Journal of Renin-Angiotensin-Aldosterone System. 2011;12(4):549-556.

12. Tsai C.T., Hwang J.J., Chiang F.T. et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation: a regression approach for the detection of gene-gene interactions in a large hospitalized population. Cardiology. 2008;111(1):1-7.

13. Ogurkova O.N., Lugacheva Y.G., Suslova T.E., et al. Polimorfizm genov faktorov sistemy gemostaza FII, FV, FGB, PAI-1 i trombocitarnyh receptorov ITGA2, ITGB3 u pacientov s fibrillyaciej predserdij (pilotnoe issledovanie) [Polymorphism of the genes of hemostatic system factors FII, FV, FGB, PAI-1 and platelet receptors ITGA2, ITGB3 in patients with atrial fibrillation (pilot study)]. Medicinskaya genetika [Medical genetics]. 2023;22(1):22-28. (In Russ.)

14. Chen J., Jing J., Tan H. et al. Lack of association of CYP11B2-344C/T polymorphism with essential hypertension: a meta-analysis. Int J Clin Exp Med. 2015;8(6):9162-9167.


Review

For citations:


Ogurkova O.N., Lugacheva Yu.G., Suslova T.E., Кulagina I.V., Dragunova M.A., Sitkova E.S., Musatova O.V., Batalov R.E. Study of polymorphism of genes of the renin-angiotensin-aldosterone system in patients with non-valvular atrial fibrillation with or without arterial hypertension (pilot study). Medical Genetics. 2024;23(4):54-62. (In Russ.) https://doi.org/10.25557/2073-7998.2024.04.54-62

Views: 172


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2073-7998 (Print)